UNION CITY, Calif.--(BUSINESS WIRE)--July 6, 2005--Questcor
Pharmaceuticals, Inc. (AMEX:QSC), a specialty pharmaceutical company
that develops and commercializes novel therapeutics for the treatment
of neurological disorders, today announced the appointment of Gregg
Lapointe to its Board of Directors.
Mr. Lapointe is Chief Operating Officer of Sigma-Tau
Pharmaceuticals, Inc. of Gaithersburg, Maryland. Sigma-Tau
Pharmaceuticals is the U.S. subsidiary of Sigma-Tau Finanziaria SpA of
Rome, Italy, Questcor's largest shareholder. Mr. Lapointe joined
Sigma-Tau in September 2001 as Vice President, Finance. In August
2002, he became Vice President, Operations, and in November 2003 he
was elected Chief Operating Officer. Before joining Sigma-Tau, Mr.
Lapointe was Vice President, Operations and Vice President, Controller
of AstenJohnson, Inc. (formerly JWI Inc.) of Charleston, South
Carolina. Mr. Lapointe holds a bachelor's degree in commerce from
Concordia University (Montreal, Canada), a graduate diploma in
accountancy from McGill University (Montreal, Canada), and a master's
degree in business administration from the Fuqua School of Business,
Duke University. He is a certified public accountant and a chartered
Mr. Lapointe serves on the board of EP Global Communications,
Inc., and is a member of the corporate council of the National
Organization for Rare Diseases (NORD), the Child Neurology Foundation
and Kidney Care Partners.
"We gladly welcome Mr. Lapointe to the Board of Directors of
Questcor," said Mr. James L. Fares, President and CEO of Questcor.
"Mr. Lapointe brings extensive business experience and skill in the
areas of strategic planning, business development, corporate finance
and acquisitions. In addition, we are very pleased that with this
appointment we now have a representative of Sigma-Tau, our largest
shareholder, on our Board of Directors."
Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty
pharmaceutical company that develops and commercializes novel
therapeutics for the treatment of neurological disorders. Questcor
currently markets four products in the U.S.: H.P. Acthar(R) Gel
(repository corticotropin injection), an injectable drug that is
commonly used for certain neurological conditions; Nascobal(R), the
only prescription nasal gel formulation of Cyanocobalamin USP (Vitamin
B12), that is approved for patients with B12 deficiency caused by
malabsorptive disorders resulting from structural or functional
damage, such as bariatric surgery, Crohn's disease and certain
neurological conditions; Ethamolin(R) (Ethanolamine Oleate), an
injectable drug used to treat enlarged weakened blood vessels at the
entrance to the stomach that have recently bled, known as esophageal
varices; and Glofil-125(R), which is an injectable agent that assesses
how well the kidney is working by measuring glomerular filtration
rate, or kidney function.
CONTACT: Questcor Pharmaceuticals, Inc.
James L. Fares, 510-400-0700
SOURCE: Questcor Pharmaceuticals, Inc.